Dr. Madden obtained his BSc. and Ph.D. in Biochemistry from the University of London, U.K. He has held senior academic and industry positions including Assistant Professor in Pharmacology at the University of British Columbia and Senior Director, Technology Development and Licensing at Tekmira Pharmaceuticals. At Tekmira Pharmaceuticals Dr. Madden was responsible for product development of several liposomal anticancer agents including Marqibo™ (liposomal vincristine). Dr. Madden founded Acuitas Therapeutics in February 2009 and through his role as President and CEO has guided the company in its corporate relationships. The collaboration he established with Alnylam Pharmaceuticals resulted in development of key delivery technology that has been translated into two RNAi therapeutics in clinical development. Dr. Madden has over 50 publications relating to LNP technology and development of pharmaceutical products.
Prior to joining Acuitas, Dr. Redelmeier was the President & CEO of Transferra Nanosciences (formerly known as Northern Lipids). He led the company for 20 years, transforming it into a recognized leader in the provision of Contract Research/Manufacturing services specifically related to lipid nanoparticle formulations of active pharmaceutical ingredients. The company was sold to EVONIK in 2016, where it continues to be active in this area.
Dr. Redelmeier has more than 30 years of experience studying lipid nanoparticle (LNP) systems including 20 years at Transferra where he was involved with more than 25 programs that were undergoing preclinical and clinical development. His extensive experience covers LNP formulations of small molecules and nucleic acids and includes the chemistry, manufacturing and control (CMC) of these complex delivery systems.
Dr. Hope obtained his BSc. and Ph.D. in Biochemistry from the University of London, U.K. He has held senior academic and industry positions including Assistant Professor in the Department of Medicine, University of British Columbia, Vice-President Research at the Canadian Liposome Company and Principal Scientist at Tekmira Pharmaceuticals before joining Acuitas. Dr. Hope has extensive experience in all aspect of liposome research including biophysical characterization and preclinical testing and development. This includes leading research teams responsible for the conduct of preclinical pharmacodynamic, pharmacokinetic and safety studies to support several Investigational New Drug (IND) applications for liposomal therapeutic products including Marqibo™, Alocrest™ and Brakiva™. Dr. Hope is an author on over 100 publications in peer-reviewed journals.
Dr. Cullis is the Life Sciences Institute Director, Professor, Department of Biochemistry and Molecular Biology and Director, NanoMedicines Research Group at the University of British Columbia. Dr. Cullis and co-workers have been responsible for fundamental advances in the generation, loading and targeting of liposomal nanoparticulate (LNP) systems for intravenous delivery of conventional and nucleic acid drugs. This work has contributed to three LNP products that have been approved by regulatory agencies in the U.S. and Europe. He has published over 290 scientific articles and is an inventor on over 40 patents. Dr. Cullis has received many awards, including the B.C. Science Council Gold Medal, the Alec D. Bangham Award and the B.C. Biotechnology Association award for Innovation and Achievement. He was elected a Fellow of the Royal Society of Canada in 2004 and was awarded the Prix Galien, Canada’s premier prize for achievements in pharmaceutical R&D, in 2011.
Dr. Tam obtained his BSc. and Ph.D. in Biology from the University of Waterloo, Ontario. He has held senior academic and industry positions including Instructor and Assistant Professor in the Department of Hematology/Oncology in the Faculty of Medicine, Rush-Presbyterian-St. Luke’s Medical Center in Chicago, IL, USA and Senior Scientist at Tekmira Pharmaceuticals before joining Acuitas. He has extensive experience in a wide range of preclinical studies with particular focus on immunology and immunotherapy. In both academic and industry positions he has lead research teams developing novel liposomal immunotherapy agents.
Dr. Tam has strong practical experienced in the design and conduct of preclinical studies including safety, pharmacodynamic and pharmacokinetic studies. As a Senior Research Scientist at Tekmira Pharmaceuticals he oversaw the conduct of preclinical studies relating to development of immune-stimulating liposomal oligonucleotide products. Dr. Tam is an author on over 45 published or submitted scientific manuscripts.